Brief: Menarini Group's Elacestrant granted priority review by the U.S. FDA for patients with Er+/Her2- advanced or metastatic breast cancer
11/08/2022 11:58
Aug 11 (Reuters) - Radius Health Inc RDUS.O :
* MENARINI GROUP'S ELACESTRANT GRANTED PRIORITY REVIEW BY
THE U.S.
FDA FOR PATIENTS WITH ER+/HER2- ADVANCED OR METASTATIC BREAST
CANCER
Source text for Eikon: ID:nCNWYZCtCa
Further company coverage: RDUS.O
Recent news on Radius Recycling
See all newsRadius Recycling Inc reports results for the quarter ended May 31 - Earnings Summary
Radius Recycling Inc expected to post a loss of 56 cents a share - Earnings Preview
Brief: Radius Recycling expects Q3 net loss of $16 million - SEC Filing
Radius Recycling Inc reports results for the quarter ended February 28 - Earnings Summary
Brief: Radius Recycling To Pay $27.2 Million Termination Fee To Toyota Tsusho America If Deal Terminated Under Specified Circumstances